



# RESEARCH OPPORTUNITIES ALERT!



**Quarter: October – December, 2012**



**Issue 11: Volume 1b (Research Grants from NIH)**

*A Compilation by the*

**Research Services Unit  
Office of Research, Innovation and Development (ORID)**

**October 2012**



# **H**UMAN HEALTH AND HEREDITY IN AFRICA (H3AFRICA): RESEARCH GRANTS (U01)

NIH: National Human Genome Research Institute

## **Description:**

Five NIH participant institutions and offices in partnership with the Wellcome Trust invite applications for their human health and heredity in Africa (H3Africa) research grants.

The purpose of this U01 funding opportunity is to invite applications from institutions in African countries for research projects that address one or more goals of the human heredity and health in Africa initiative. H3Africa is an NIH initiative in partnership with the Wellcome Trust with the goals of developing the study of genomic/genetic/environmental contributors to human health and disease within Africa using cutting-edge genomic research tools, increasing capacity for biomedical research in Africa, in terms of building the infrastructure needed for genomic research (including data and research resources), and increasing the genomic proficiency of researchers and trainees in Africa. The H3Africa Initiative is focused on supporting these efforts as part of an effort to promote sustainable research in Africa that will promote health and combat disease.

This FOA utilises the research projects - cooperative agreement U01 funding mechanism and runs parallel with four FOAs with similar scope, RFA-RM-12-006 human heredity and health in Africa (H3Africa) collaborative centres cooperative agreements (U54); RFA-RM-12-008 human heredity and health in Africa (H3Africa) biorepositories (UH2/UH3); RFA-RM-11-010 human heredity and health in Africa (H3Africa) bioinformatics network cooperative agreements (U41); RFA-RM-12-005, human heredity and health in Africa (H3Africa) ethical, legal and societal issues research programme (U01).

The total amount of funds available for these awards is approximately US\$1.4 million per year for fiscal years 2013 to 2016. A maximum of four awards will be funded. Applications are limited to US\$350,000 total costs per year, for a maximum of four years, which includes salaries, supplies, training, equipment, travel, and other allowed expenses for research grants.

Non-domestic components of US organisations and African entities, including public and private institutions of higher education, are eligible to apply. RFA-RM-12-007 (replaces RFA-RM-12-004)

**Closing date: 29 Oct 12**

**Deadline information: Letters of intent due by 28 September; full applications due by 5pm local time of applicant organisation on 29 October 2012.**

**Posted date: 23 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Institutional development**

**Award amount max: \$1,400,000**

**Award amount min: -**

**Award budget total: \$5,600,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-007.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-RM-12-007>

## **Eligibility profile**

Nationality of applicant institution: All African Nations

## **Disciplines**

Africa, Central, Africa, Eastern, Africa, Northern, Africa, Southern, Africa, Sub-

Saharan, Africa, Western, Transmission of HIV/AIDS, Human Population Genetics, Population Genetics, Biomedical Research, Multidisciplinary, AIDS, HIV Infection, Infectious Diseases & Agents, Education & Instruction (Health & Safety & Medical), Biomedical Research Training, Environment (Health & Safety & Medical), Environmental Health, Environmental Medicine, Research Resources (Health & Safety & Medical), Biomedical Research Resources, Other, Specialties of Medical & Allied Fields, Medical Genetics, Technology Assessment & Transfer & Outreach (Health & Medical), Genetics, Environmental Impact, Health Effects, Human Genome, Clinical Laboratory Sciences (RAE Unit 1), Pharmacology (RAE Unit 8), Other Studies and Professions Allied

to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Bioinformatics / Health Informatics, Genomics, Clinical Laboratory Science, Other Studies and Professions Allied to Medicine, Chronic Diseases, Pharmacogenomics

#### Contact Details

-----  
National Human Genome Research Institute  
NIH  
5635 Fishers Lane  
Suite 4076  
MSC 9305  
Tel: +1 301 496 7531  
Fax: +1 301 480 2770  
Email: [jane.peterson@nih.gov](mailto:jane.peterson@nih.gov)

## **H**UMAN HEALTH AND HEREDITY IN AFRICA (H3AFRICA): COLLABORATIVE CENTRES (U54) *NIH: National Human Genome Research Institute*

### Description:

Four NIH participant institutions and offices in partnership with the Wellcome Trust invite applications for their human health and heredity in Africa (H3Africa) collaborative centres grants. This U54 funding opportunity announcement invites applications from institutions in African countries for research centres called H3Africa collaborative centres. This FOA is a component of the Human Health and Heredity in Africa Initiative (H3Africa), an NIH initiative in partnership with the Wellcome Trust to develop the study, in Africa, of genomic/genetic/environmental contributors of human health and disease within Africa using cutting-edge genomic research tools, to increase capacity for biomedical research in Africa, in terms of building infrastructure (including data and research resources), and to increase the genomic proficiency of researchers and trainees in Africa. The H3Africa Initiative is

focused on supporting these efforts as part of an effort to promote sustainable research in Africa that will promote health and combat disease.

This FOA utilises U54 specialised centre - cooperative agreements funding mechanism and runs parallel with four FOAs with similar scope, RFA-RM-12-007, human heredity and health in Africa (H3Africa) research grants (U01); RFA-RM-12-008, human heredity and health in Africa (H3Africa) biorepositories (UH2/UH3); RFA-RM-11-010 human heredity and health in Africa (H3Africa) bioinformatics network cooperative agreements (U41); RFA-RM-12-005, human heredity and health in Africa (H3Africa) ethical, legal and societal issues, research programme (U01).

The total amount of funds available for these awards is approximately US\$2.5 million for fiscal year 2013, and US\$2m per year for

fiscal years 2014 to 2016. Up to two awards are anticipated to be funded.

Applications are limited to US\$1 million per year total costs which includes salaries, supplies, training, equipment, travel, and other allowed expenses for research grants. Each applicant may request up to an additional US\$250,000 for equipment in the first year. In subsequent years the research plan budget may not exceed US\$1 million direct costs. US\$35,000 direct costs per year must also be set aside for participation in the international extramural administrative research development programme. The maximum project period is four years. Non-domestic components of US organisations and African entities, including public and private institutions of higher education, are eligible to apply. RFA-RM-12-006 (replaces RFA-RM-11-008).

**Closing date: 29 Oct 12**

**Deadline information: Letters of intent due by 28 September; full applications due by 29 October 2012.**

**Posted date: 23 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Equipment and materials, Research centres, Networking/collaboration**

**Award amount max: \$4,250,000**

**Award amount min: -**

**Award budget total: \$8,500,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-006.html>

**Application form:**

<http://grants.nih.gov/grants/funding/phs398/phs398.html>

**Eligibility profile**

-----

Nationality of applicant institution: All African Nations

### **Disciplines**

-----

Africa, Central, Africa, Eastern, Africa, Northern, Africa, Southern, Africa, Sub-Saharan, Africa, Western, Transmission of HIV/AIDS, Human Population Genetics, Population Genetics, Biomedical Research, Multidisciplinary, AIDS, HIV Infection, Infectious Diseases & Agents, Education & Instruction (Health & Safety & Medical), Biomedical Research Training, Environment (Health & Safety & Medical), Environmental Health, Environmental Medicine, Research Resources (Health & Safety & Medical), Biomedical Research Resources, Other, Specialties of Medical & Allied Fields, Medical Genetics, Technology Assessment & Transfer & Outreach (Health & Medical), Genetics, Environmental Impact, Health Effects, Human Genome, Clinical Laboratory Sciences (RAE Unit 1), Pharmacology (RAE Unit 8), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Bioinformatics / Health Informatics, Genomics, Clinical Laboratory Science, Other Studies and Professions Allied to Medicine, Chronic Diseases, Pharmacogenomics

### **Contact**

-----

National Human Genome Research Institute  
NIH  
5635 Fishers Lane  
Suite 4076  
MSC 9305  
Tel: +1 301 496 7531  
Fax: +1 301 480 2770  
Email: [Jane.Peterson@nih.gov](mailto:Jane.Peterson@nih.gov)



# **H**UMAN HEREDITY AND HEALTH IN AFRICA (H3AFRICA): H3AFRICA **BIOREPOSITORY GRANTS (UH2/UH3)** NIH: National Human Genome Research Institute

## **Description:**

The National Human Genome Research Institute, in partnership with the Wellcome Trust, invites applications for the human heredity and health in Africa (H3Africa) biorepository grants.

The purpose of this UH2/UH3 funding opportunity announcement is to provide funding to develop plans for an H3Africa biorepository, building upon existing infrastructure, in order to provide an international site for the receipt, storage and distribution of samples from H3Africa research projects as well as other African research studies. Applications should include plans for initial two-year UH2 phase I studies as well as plans for an additional four years of support for implementing a full-scale H3Africa Biorepository, beginning in 2014.

This FOA uses the phase innovation awards cooperative agreement (UH2/UH3) funding instrument and runs in parallel with four FOAs of similar scope: RFA-RM-12-006, human heredity and health in Africa (H3Africa) collaborative centres cooperative agreements (U54); RFA-RM-12-007, human heredity and health in Africa (H3Africa) research projects cooperative agreements (U01); RFA-RM-11-010 human heredity and health in Africa (H3Africa) bioinformatics network cooperative agreements (U41); RFA-RM-12-005 human heredity and health in Africa (H3Africa), ethical, legal and societal issues research programme.

For the UH2 (phase I) period an estimated total of US\$400,000 will be available over two years. For the UH3 (Phase II) period, up to US\$16 million total costs for four years

beyond the UH2 Phase I phase will be available to support up to three full-scale

biorepositories. Funding per year will vary depending upon the number of biorepositories funded. Up to US\$125,000 total costs per year for the first two years, is allowed for Phase I. If only one Phase I grant is awarded, the award will be adjusted. For the Phase II period the budget is limited to US\$2m total costs in fiscal year 2015 and US\$1.7 million total costs in fiscal years 2016 to 2018. Non-domestic components of US organisations and African entities, including public and private institutions of higher education, are eligible to apply. RFA-RM-12-008 (replaces RFA-RM-12-003).

**Closing date: 29 Oct 12**

**Deadline information: Letters of intent due by 28 September; full applications due by 5pm local time of applicant organisation on 29 October, 2012.**

**Posted date: 23 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Institutional development**

**Award amount max: \$7,350,000**

**Award amount min: -**

**Award budget total: \$16,400,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-008.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-RM-12-008>

**Eligibility profile**

-----  
 Nationality of applicant institution: All African Nations

**Disciplines**

-----  
 Africa, Central, Africa, Eastern, Africa, Northern, Africa, Southern, Africa, Sub-Saharan, Africa, Western, Transmission of HIV/AIDS, Human Population Genetics,



Population Genetics, Biomedical Research, Multidisciplinary, AIDS, HIV Infection, Infectious Diseases & Agents, Education & Instruction (Health & Safety & Medical), Biomedical Research Training, Environment (Health & Safety & Medical), Environmental Health, Environmental Medicine, Research Resources (Health & Safety & Medical), Biomedical Research Resources, Other, Specialties of Medical & Allied Fields, Medical Genetics, Technology Assessment & Transfer & Outreach (Health & Medical), Genetics, Environmental Impact, Health Effects, Human Genome, Clinical Laboratory Sciences (RAE Unit 1), Pharmacology (RAE Unit 8), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological

Sciences (RAE Unit 14), Bioinformatics / Health Informatics, Genomics, Clinical Laboratory Science, Other Studies and Professions Allied to Medicine, Chronic Diseases, Pharmacogenomics

#### Contact Details

-----  
National Human Genome Research Institute  
NIH  
5635 Fishers Lane, Suite 4076, MSC 9305  
Bethesda, MD 20892-9305  
Tel: +1 301 496 7531  
Fax: +1 301 480 2770  
Email: [Jane.Peterson@nih.gov](mailto:Jane.Peterson@nih.gov)

---

## **H**UMAN HEREDITY AND HEALTH IN AFRICA: ETHICAL, LEGAL AND SOCIETAL ISSUES RESEARCH PROGRAMME (U01) *NIH: Office of the Director*

#### Description:

The National Institute of Health's Office of Strategic Coordination and the National Human Genome Research Institute invites applications for their human heredity and health in Africa: ethical, legal and societal issues research programme (U01). This U01 funding opportunity announcement encourages applications to study the ethical, legal and societal issues of human genome research in African populations. Projects that propose focused bioethical, legal and social science analyses of new or emerging issues are of particular interest. This funding opportunity announcement will use the U01 cooperative agreement award mechanism. Eligible applicants include African public, state and private higher education institutions. Three or four projects may be funded with up to US\$50,000 each per year over three years in direct costs. The total anticipated budget is US\$162,000 per year for three years. RFA-RM-12-005.

**Closing date: 29 Oct 12**

**Deadline information: Optional letters of intent due by 29 September, applications due by 5pm local time, 29 October 2012.**

**Posted date: 14 Jun 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$150,000**

**Award amount min: -**

**Award budget total: \$486,000**

#### Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-005.html>

#### Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-RM-12-005>

#### Eligibility profile

-----  
Nationality of applicant institution: All African Nations

## Disciplines

---

Africa, Central, Africa, Eastern, Africa, Northern, Africa, Southern, Africa, Sub-Saharan, Africa, Western, Bioethics, Social Sciences, Legal Systems, Mapping, Genetic, Legal Procedure, Legal Reform, Human Genome, Psychology (RAE Unit 13), Biological Sciences (RAE Unit 14), Geography (RAE Unit 35), Law (RAE Unit 36), Anthropology (RAE Unit 37), Social Policy and Administration (RAE Unit 40), Middle

Eastern and African Studies (RAE Unit 46), Middle Eastern and African Studies

## Contact Details

---

NHGRI  
NIH  
530 Davis Drive, Room 3130  
Morrisville, NC 27560  
Tel: +1 919 541 0367  
Email: [ebony.bookman@nih.gov](mailto:ebony.bookman@nih.gov)

---

## **B**ASIC BEHAVIOURAL RESEARCH ON MULTISENSORY PROCESSING (R21) *NIH: National Eye Institute*

### Description:

The National Institutes of Health basic behavioural and social science opportunity network and its member institutes, centres and offices invite applications for the basic behavioural research on multisensory processing (R21) grants. This R21 funding opportunity announcement encourages research grant applications investigating multisensory processing in perception and other behavioural outcomes. The FOA is intended to support basic behavioural research project focused on two or more sensory modalities. This includes research examining ways in which cognitive or affective processes interact with multisensory input to influence basic behavioural targets. Research is currently underdeveloped with regard to how different modalities are integrated for perception and behavioural or social outcomes.

The participating ICs intend to commit approximately US\$1.5 million to fund approximately six awards in fiscal year 2013. Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit

and non-profit organisations and public or private institutions are eligible to apply. RFA-EY-13-001.

**Closing date: 31 Oct 12**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 03 Sep 12**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-EY-13-001.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=RFA-EY-13-001>

### Eligibility profile

---

Nationality of applicant institution: Any

### Disciplines

---

Behavioural Studies & Social Problems, Aural Perception, Cognitive Development & Processes, Perception, Visual Perception, Affective Development, Sensory System,



Behaviour & Health, Physical Senses, Other, Biological Sensor Mechanisms, Biology, Behavioural, Psychology (RAE Unit 13), Biological Sciences (RAE Unit 14), Education (RAE Unit 68), Olfaction, Human Taste, Human Smell

**Contact Details**

-----  
National Eye Institute  
31 Center Drive  
Bethesda, MD 20892-2510  
Tel: +1 301 451 2020  
Email: [wiggsc@mail.nih.gov](mailto:wiggsc@mail.nih.gov)



**NOVEMBER 2012**

## **M**OLECULAR MECHANISMS OF CIRCADIAN CLOCKS IN AGEING TISSUES (R01) NIH: National Institute on Aging

### **Description:**

The National Institute on Aging invites applications for its molecular mechanisms of circadian clocks in ageing tissues (R01) grants. This R01 funding opportunity announcement aims to enhance understanding of the molecular mechanisms that control circadian clocks in ageing tissues. The FOA encourages studies on the roles of peripheral and extra suprachiasmatic nucleus circadian clocks during ageing. These studies include understanding the impact of alterations in the clock system on chromatin remodelling, gene expression, translation, signalling and function of individual cells. In addition, NIA solicits studies on the pathophysiology of alterations to circadian clock regulation in aged tissues, with particular attention to the response of the clock system to metabolic and nutritional, environmental and pharmacological challenges.

NIA intends to commit US\$1.5 million in fiscal year 2013 to fund five to six awards. Application budgets are limited to US\$200,000 direct costs in any year. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. RFA-AG-13-007.

**Closing date: 07 Nov 12**

**Deadline information: Applications due by 5pm proposer's local time.**

**Posted date: 17 Aug 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$1,000,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-007.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-AG-13-007>

### **Eligibility profile**

-----  
 Nationality of applicant institution: Any

### **Disciplines**

-----  
 Human Population Genetics, Ageing & Gerontology, Gene Expression, Membrane Structure & Function, Nucleic Acid Structure & Function, Biology, Cellular, Biology, Molecular, DNA Mapping, Molecular Genetics, Chemical Signaling, Clinical Laboratory Sciences (RAE Unit 1), Biological Sciences (RAE Unit 14), Chemistry (RAE Unit 18), Clinical Laboratory Science, Cellular Pathology, Circadian Rhythms

### **Contact Details**

-----  
 Cell Biology Programme  
 Division of Ageing Biology  
 NIA  
 7201 Wisconsin Avenue, Suite 2C231  
 Bethesda, MD 20892-9205  
 Tel: +1 301 496 6428  
 Fax: +1 301 402 0010  
 Email: [jvelazqu@mail.nih.gov](mailto:jvelazqu@mail.nih.gov)

## **C**ORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (UM1) NIH: National Cancer Institute

### **Description:**

The National Cancer Institute invites applications for its core infrastructure and methodological research for cancer epidemiology cohorts calls. This call supports UM1 grant applications to provide targeted infrastructure support for the core functions of cancer epidemiology cohorts (CECs) and methodological research. This infrastructure can support existing or new CECs. This funding opportunity announcement will support core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genetics Program and other components of the Division of Cancer Control and Population Sciences at the National Cancer Institute. Support is envisioned for two types of CECs through this FOA:

- CECs with at least 10,000 study participants that are capable of supporting studies to examine the effects of multiple exposures and study participants' characteristics on the risk of multiple types of incident cancers and cancer mortality;
- cohorts of cancer patients including at least 10,000 participants for research addressing determinants of cancer prognosis, progression, and cancer-related outcomes among cancer survivors such as cancer recurrence, development of new primaries, survival, and health conditions and chronic diseases related to the cancer, cancer-directed therapy, or its consequences.

This FOA will utilize the UM1 cooperative agreement award mechanism. Budget durations are not limited, but must reflect the actual needs of the project. A project duration of up to five years may be requested. Eligible organizations include domestic and foreign

public and private non-profit organizations and for-profit organizations. PAR-11-167 (replaces PAR-10-283)

**Closing date: 08 Nov 12**

**Deadline information: Deadlines on: 8 March 2011, 6 July 2011, 10 November 2011, 6 March 2012, 6 July 2012, 8 November 2012, 8 March 2013, 10 July 2013, 8 November 2013.**

**Posted date: 23 Mar 11**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration, Research centres**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-10-283.html>

**Application form:**

<http://grants.nih.gov/grants/funding/phs398/phs398.pdf>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Cancer Biology, Cancer & Carcinogenesis, Epidemiology, Clinical Laboratory Sciences (RAE Unit 1), Clinical Laboratory Science

### **Contact Details**

-----  
Division of Cancer Control and Population Sciences

National Cancer Institute, NIH

6130 Executive Boulevard, EPN Room 6142, MSC 7338

Bethesda, MD 20892-7338

Tel: +1 301 594 9499

Fax: +1 391 435 6609

Email: [winnde@mail.nih.gov](mailto:winnde@mail.nih.gov)

## **E**ARLY PHASE CLINICAL TRIALS IN IMAGING AND IMAGE-GUIDED INTERVENTIONS (R21) NIH: National Cancer Institute

### **Description:**

The National Cancer Institute invites applications for its early phase clinical trials in imaging and image-guided interventions (R21) grants. This R21 funding opportunity announcement is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3D reconstruction and other quantitative tools. This FOA will provide investigators with support for pilot cancer imaging clinical trials, including patient monitoring and laboratory studies. If proven successful, these investigations can be validated in larger studies through competitive R01 mechanisms or other clinical trials.

This FOA will use the NIH exploratory/developmental (R21) grant mechanism. Direct costs are limited to \$500,000 over a two-year period, with no more than \$250,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-216

**Closing date: 13 Nov 12**

**Deadline information: Deadlines: by 5 pm, July 27 and November 10, 2011; March 13, July 11 and November 13, 2012; March 13, July 11 and November 13, 2013; March 13, 2014.**

**Posted date: 26 May 11**

**Award type: Directed grants to institutions, research groups etc, Clinical trials**

**Award amount max: \$500,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-216.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-216>

### **Eligibility profile**

-----  
 Nationality of applicant institution: Any

### **Disciplines**

-----  
 Medical & Diagnostic Imaging, Cancer & Carcinogenesis, Disease Model, Mathematical Model (Medical), Imaging, Clinical Laboratory Sciences (RAE Unit 1), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Applied Mathematics (RAE Unit 23), Computer Science (RAE Unit 25), Electrical and Electronic Engineering (RAE Unit 29), Clinical Laboratory Science, Other Studies and Professions Allied to Medicine

### **Contact Details**

-----  
 Cancer Imaging Program  
 Division of Cancer Treatment and Diagnosis  
 NCI  
 6130 Executive Boulevard, EPN Room 6048,  
 MSC 7412  
 Bethesda, MD 20852-7412  
 Tel: +1 301 496 9531  
 Fax: +1 301 480 3507  
 Email: [shankarl@mail.nih.gov](mailto:shankarl@mail.nih.gov)

## UNDERSTANDING THE FUNCTIONS OF UNCHARACTERISED GENES IN INFECTIOUS DISEASE PATHOGENS (U19)

NIH: National Institute of Allergy and Infectious Diseases

### Description:

The National Institute of Allergy and Infectious Diseases invites applications for its understanding the functions of uncharacterised genes in infectious disease pathogens (U19) call. The purpose of this U19 funding opportunity announcement is to create a programme to conduct fundamental genomics research that will increase knowledge of the specific biochemical functions of hypothetical genes and unknown open reading frames, and the functions of non-coding RNAs in the annotated genomes of infectious disease pathogens. All applicants must propose to study a minimum of 10 genes per year in each of the three categories of uncharacterised genes and include a focus on one or more NIAID category A-C pathogens and emerging or re-emerging pathogens.

Each application must include an administrative core headed, by the contact principal investigator, development and maintenance of one or more core resources or facilities that are essential for generating experimental evidence, and a data management and resource dissemination core.

NIAID intends to commit US\$7.1 million in fiscal year to fund three to five awards. Application budgets are not limited, but must reflect the actual needs of the projects. The maximum award period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. RFA-AI-12-028.

**Closing date: 13 Nov 12**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 23 Jul 12**

**Award type: Directed grants to institutions, research groups etc, Research centres**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-028.html>

**Application form:**

<http://grants.nih.gov/grants/funding/phs398/phs398.html>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Infectious Diseases & Agents, Aetiology, Genetic Manipulation, Mapping, Genetic, Nucleic Acid Sequencing, Biochemical Markers, Gene Expression, Gene Regulation, Pathogenesis, Clinical Medicine, General, Medical Genetics, Pathology, DNA & RNA Hybrids, DNA Mapping, Genetics, Microbial Processes, Biochemistry, Biochemistry, Nucleic Acid, Biochemistry, Proteins, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Physiology (RAE Unit 7), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Chemistry (RAE Unit 18), Clinical Laboratory Science, Clinical Biochemistry, RNAi (RNA interference), Community-based Clinical Subjects, Hospital-based Clinical Subject, Physiology, Life Science (Bioscience)

**Contact Details**

-----  
Division of Microbiology and Infectious Diseases

NIAID

Room 4807, MSC-6603



6610 Rockledge Drive  
Bethesda, MD 20892-6603  
Tel: +1 301 496 1884

Fax: +1 301 4810 4528  
Email: [mgiovanni@niaid.gov](mailto:mgiovanni@niaid.gov)

---

## **R**EFERENCE PROFILES OF HUMAN EXTRACELLULAR RNA (U01) *NIH: Office of the Director*

### **Description:**

The National Institutes of Health Office of Strategic Coordination invites applications for its reference profiles of human extracellular RNA (U01) call. This U01 funding opportunity announcement proposes to develop reference profiles for non-coding regulatory extracellular RNAs from healthy human blood and other body fluid samples such as saliva, urine, breast milk, semen, amniotic fluid, cerebrospinal fluid, ascites and pleural effusions. Studies using existing human biospecimen collections are strongly encouraged. This FOA is only for studies related to human samples; animal or other non-human disease model studies are not responsive to this FOA.

This funding opportunity uses the U01 research programme cooperative agreement mechanism and runs in parallel with the following FOAs of identical scientific scope: RFA-RM-12-012, which uses the U19 research project cooperative agreement mechanism; RFA-RM-12-013, which uses the UH2/UH3 phase innovation awards cooperative agreement mechanism; and RFA-RM-12-014, which also uses the UH2/UH3 phase innovation awards cooperative agreement mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

NIH intends to fund an estimate of three to five awards, corresponding to a total of US\$4 million per year. Direct costs are limited to US\$700,000 over a maximum five-year project period. RFA-RM-12-011.

**Closing date: 13 Nov 12**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 06 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration**

**Award amount max: \$700,000**

**Award budget total: \$20,000,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-011.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-RM-12-011>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Food Analysis, Food & Optimal Health, Environmental Health, Blood, Blood Products & Transfusions, Breast Milk, Nucleic Acid Sequencing, Membrane Structure & Function, Nucleic Acid Structure & Function, Biology, Cellular, DNA & RNA Hybrids, Physiological Processes, Physiology, Human, Clinical Laboratory Sciences (RAE Unit 1), Physiology (RAE Unit 7), Biological

Sciences (RAE Unit 14), Food Science and Technology (RAE Unit 16), Clinical Laboratory Science, Physiology

6701 Rockledge Drive, Room 10184  
2 Rockledge Center  
Bethesda, MD 20892  
Tel: +1 301 402 3712  
Email: [srinivap@nhlbi.nih.gov](mailto:srinivap@nhlbi.nih.gov)

#### Contact Details

-----  
National Heart Lung and Blood Institute



## **EXTRACELLULAR RNA BIOGENESIS, BIODISTRIBUTION, UPTAKE AND EFFECTOR FUNCTION (U19)** *NIH: Office of the Director*

### **Description:**

The National Institutes of Health Office of Strategic Coordination invites applications for its extracellular RNA biogenesis, biodistribution, uptake and effector function (U19) call. This U19 funding opportunity announcement invites applications for projects to determine the principles that guide the selection of regulatory RNA molecules for extracellular transport and to determine the function of these extracellular RNAs. The main scientific areas of interest include:

- exRNA biogenesis;
- exRNA biodistribution;
- uptake of exRNA by target cells;
- the physiological impact of delivered exRNA in target cells and tissues.

Enabling tools, technologies, bioreagents, and innovative analytical approaches will likely be required to achieve the research goals. Therefore, awards funded under this FOA are anticipated to involve research conducted by multidisciplinary teams of investigators and focus on the role of exRNA communication in health and disease.

This funding opportunity uses the U19 research project cooperative agreement mechanism and runs in parallel with the following FOAs of identical scientific scope,

RFA-RM-12-011, which uses the U01 research project cooperative agreement mechanism; RFA-RM-12-013, which also uses the UH2/UH3 phase innovation awards cooperative agreement mechanism; and RFA-RM-12-014, which also uses the UH2/UH3 phase innovation awards cooperative agreement mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

NIH intends to fund an estimate of four to six awards, with a total of US\$7.2 million per year. Application budgets are not limited but must reflect the actual needs of the project. RFA-RM-12-012.

**Closing date: 13 Nov 12**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 06 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-012.html>

**Application form:**

<http://grants.nih.gov/grants/funding/phs398/phs398.html>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Food Analysis, Food & Optimal Health, Environmental Health, Blood, Blood Products & Transfusions, Breast Milk, Nucleic Acid Sequencing, Biochemical Markers, Biological Markers, Membrane Structure & Function, Nucleic Acid Structure & Function, Biology, Cellular, DNA & RNA

Hybrids, Physiological Processes, Physiology, Human, Clinical Laboratory Sciences (RAE Unit 1), Physiology (RAE Unit 7), Biological Sciences (RAE Unit 14), Food Science and Technology (RAE Unit 16), Clinical Laboratory Science, Physiology

**Contact Details**

Cancer Immunology and Hematology Branch  
Division of Cancer Biology  
National Cancer Institute  
6130 Executive Boulevard  
EPN Room 5060 MSC 7388  
Bethesda, MD 20892-7388  
Tel: +1 301 496 7815  
Email: [howcrofk@mail.nih.gov](mailto:howcrofk@mail.nih.gov)

---

**C** LINICAL UTILITY OF EXTRACELLULAR RNA FOR BIOMARKER DEVELOPMENT (UH2/UH3)

*NIH: Office of the Director*

**Description:**

The National Institutes of Health Office of Strategic Coordination invites applications for its clinical utility of extracellular RNA for biomarker development (UH2/UH3) call. This UH2/UH3 funding opportunity announcement invites applications for projects that will identify and qualify extracellular RNA-based biomarkers derived from human body fluids, such as blood, saliva, urine, breast milk, amniotic fluid, cerebrospinal fluid, ascites and pleural effusions, in order to diagnose and monitor disease progression and response to therapy. The overall goal of this project is to develop reliable, well-defined and clinically relevant biomarkers derived from extracellular RNA that measure tangible benefits for patients in terms of how they feel, function, and survive in clinical trials. Appropriate studies under this FOA will identify and validate candidate exRNA-based biomarkers in well-defined patient populations, provide new

technologies to monitor biomarkers or establish reliable assays for validated markers. Studies using existing human biospecimen collections are strongly encouraged. This FOA is only for studies related to human biomarkers; animal or other non-human disease model studies are not responsive to this FOA.

This funding opportunity uses the UH2/UH3 cooperative agreement award mechanism. The initial UH2 phase will support studies of up to two years to identify and develop exRNA-based biomarkers from human body fluids. Transition to qualification and validation studies in the remaining three to four years will be supported during the UH3 phase. Awards funded under this FOA are anticipated to involve activities conducted by multidisciplinary teams of investigators.

This FOA runs in parallel with the following FOAs of identical scientific scope, RFA-RM-

12-011, which uses the U01 research programme cooperative agreement mechanism; RFA-RM-12-012, which uses the U19 research programme cooperative agreement mechanism; and RFA-RM-12-014, which also uses the UH2/UH3 phase innovation awards cooperative agreement mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Total funding for the UH2 phase is US\$4 million per year and will support between six and eight awards. Total funding for the UH3 phase is US\$6m to US\$8m. Applicants may request up to US\$500,000 total costs for the UH2 phase and US\$1m for the UH3 phase. The maximum combined total project period is five years. RFA-RM-12-013.

**Closing date: 13 Nov 12**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 06 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration, Innovation grants**

**Award amount max: \$1,500,000**

**Award amount min: -**

**Award budget total: -**

#### **Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-013.html>

#### **Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-RM-12-013>

#### **Eligibility profile**

Nationality of applicant institution: Any

#### **Disciplines**

Food Analysis, Food & Optimal Health, Environmental Health, Blood, Blood Products & Transfusions, Breast Milk, Nucleic Acid Sequencing, Membrane Structure & Function, Nucleic Acid Structure & Function, Biology, Cellular, DNA & RNA Hybrids, Physiological Processes, Physiology, Human, Clinical Laboratory Sciences (RAE Unit 1), Physiology (RAE Unit 7), Biological Sciences (RAE Unit 14), Food Science and Technology (RAE Unit 16), Clinical Laboratory Science, Physiology

#### **Contact Details**

National Institute of Neurological Disorders and Stroke

6001 Neuroscience Center, Room 2114

6001 Executive Blvd.

Bethesda, MD 20895

Tel: +1 301 496 5745

Email: [tagled@ninds.nih.gov](mailto:tagled@ninds.nih.gov)

## **C**LINICAL UTILITY OF EXTRACELLULAR RNA FOR THERAPY DEVELOPMENT (UH2/UH3)

NIH: Office of the Director

#### **Description:**

The National Institutes of Health Office of Strategic Coordination invites applications for its clinical utility of extracellular RNA for therapy development (UH2/UH3) call. This UH2/UH3 funding opportunity

announcement invites applications for projects that will develop novel therapies based on exRNA signaling. The overall goal of this initiative is to develop and demonstrate the potential for clinical utility of exRNAs as therapeutic agents, and to

develop tools and technologies to enable engineered RNAs to be packaged into extracellular vesicles or associated with RNA-binding proteins for use as extracellular delivery vehicles. These projects should include methods for the production, purification, and packaging of specific RNAs and methods to deliver them to target cells via extracellular space. This FOA will support highly innovative and novel use of exRNA in therapy development and delivery. Slight modifications or incremental advances over existing approaches will not be considered responsive to this FOA.

This funding opportunity uses the UH2/UH3 cooperative agreement award mechanism. The initial UH2 phase will support exRNA-based therapy development towards milestone-driven feasibility and proof-of-concept pre-clinical studies in cell and animal models of disease. The UH3 phase will support milestone-driven pre-clinical studies to assess the clinical efficacy of a therapy for its potential new use in the proposed disease population. The project period for the UH3 phase is up to three years.

This FOA runs in parallel with the following FOAs of identical scientific scope, RFA-RM-12-011, which uses the U01 research programme cooperative agreement mechanism, RFA-RM-12-012, which uses the U19 research project cooperative agreement mechanism, and RFA-RM-12-013, which uses the UH2/UH3 phase innovation awards cooperative agreement mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Total funding for the UH2 phase is US\$4 million per year and will support between six and eight awards. Total funding for the UH3 phase is US\$6m to US\$8m. Applicants may request up to US\$500,000 total costs for the UH2 phase and US\$1m for the UH3 phase.

The maximum combined total project period is five years. RFA-RM-12-014.

**Closing date: 13 Nov 12**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 06 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration, Innovation grants**

**Award amount max: \$1,500,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-014.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-RM-12-014>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Food Analysis, Food & Optimal Health, Environmental Health, Blood, Blood Products & Transfusions, Breast Milk, Nucleic Acid Sequencing, Membrane Structure & Function, Nucleic Acid Structure & Function, Biology, Cellular, DNA & RNA Hybrids, Physiological Processes, Physiology, Human, Clinical Laboratory Sciences (RAE Unit 1), Physiology (RAE Unit 7), Biological Sciences (RAE Unit 14), Food Science and Technology (RAE Unit 16), Clinical Laboratory Science, Physiology

**Contact Details**

-----  
National Institute of Neurological Disorders and Stroke

6001 Neuroscience Center, Room 2114

6001 Executive Blvd.

Bethesda, MD 20895

Tel: +1 301 496 5745

Email: [tagled@ninds.nih.gov](mailto:tagled@ninds.nih.gov)



## **T**HE ROLE OF MICROBIAL METABOLITES IN CANCER PREVENTION AND ETIOLOGY (U01)

NIH: National Cancer Institute

### **Description:**

The National Cancer Institute and the National Center for Complementary and Alternative Medicine invite applications for their role of microbial metabolites in cancer prevention and etiology program. This U01 funding opportunity supports applications that characterize the effects of microbially generated metabolites of dietary components on host cell biology. Specifically, this funding opportunity announcement seeks to characterize microbially generated metabolites and better understand their molecular mechanisms of action that affect host cell proliferative/apoptotic responses, cytokine production, inflammatory and immunomodulatory effects. The FOA will also encourage the conduct of human intervention studies that identify inter-individual variability among various racial and ethnic groups in the production of bacterial metabolites and determine their efficacy in cancer prevention. One of the goals of this program will be to facilitate interdisciplinary collaborations among scientists engaged in nutrition, cancer prevention, cancer cell biology research, and cancer disparities research with those conducting studies with gut microorganisms. All applications must include multiple principle investigators with different areas of expertise such as microbiology, nutrition, cancer biology, analytical chemistry or genetics. Investigators may use either clinical or preclinical approaches.

This FOA will utilize the U01 cooperative agreement mechanism. Application budgets are not limited, but need to reflect actual needs of the project. Projects may have a duration of up to five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-152 (replaces PAR-10-208)

**Closing date:** 15 Nov 12

**Deadline information:** Deadline: letters of intent October 15; full applications November 15, 2011 and 2012.

**Posted date:** 17 Mar 11

**Award type:** Directed grants to institutions, research groups etc, Networking/collaboration

**Award amount max:** -

**Award amount min:** -

**Award budget total:** -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-152.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-152>

### **Eligibility profile**

Nationality of applicant institution: Any

### **Disciplines**

Cancer Biology, Breast Cancer, Cancer & Carcinogenesis, Prostate Cancer, Disease Prevention, Aetiology, Molecular & Cellular Entities, Cell Components, Anatomy, Biology, Cellular, Microbiology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Biological Sciences (RAE Unit 14), Complementary Medicine, Alternative Medicine, Clinical Laboratory Science, Blood Cancer, Cancer Nanotechnology, Community-based Clinical Subjects, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer

### **Contact Details**

Division of Cancer Prevention

NCI  
6130 Executive Boulevard, Suite 3160, MSC  
7328  
Rockville, MD 20892-7328

Tel: +1 301 594 9692  
Fax: +1 301 480 3925  
Email: [davisci@mail.nih.gov](mailto:davisci@mail.nih.gov)

---

## **S** MALL GRANTS PROGRAM FOR CANCER EPIDEMIOLOGY (R03) *NIH: National Cancer Institute*

**Description:** The National Cancer Institute invites applications for its small grants program for cancer epidemiology. The goal of this R03 funding opportunity announcement is to provide support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology.

Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. This funding opportunity will utilize the NIH R03 small grant award mechanism. Budgets for direct costs of up to \$50,000 per year for a project duration of up to two years may be requested. PAR-12-039 (replaces PAR-08-237)

**Closing date:** 19 Nov 12

**Deadline information:** Deadline: March 19, June 17, November 19, 2012; March 19, July 23, November 19, 2013; March 18, July 22, November 18, 2014.

**Posted date:** 29 Nov 11

**Award type:** Directed grants to institutions, research groups etc

**Award amount max:** \$100,000

### **Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-039.html>

### **Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-039>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Breast Cancer, Cancer & Carcinogenesis, Prostate Cancer, Aetiology, Biochemical Markers, Biological Markers, Epidemiology, Oncology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects

### **Contact Details**

-----  
Division of Cancer Control and Population Sciences

National Cancer Institute

6130 Executive Boulevard, EPN Room 5104, MSC 7324

Bethesda, MD 20892-7328

**Tel:** +1 301 594 7344

**Fax:** +1 301 402 4279

**Email:** [vermam@mail.nih.gov](mailto:vermam@mail.nih.gov)

## **I** DENTIFICATION AND ANALYSIS OF CAUSAL VARIANTS: FOLLOW-UP ON GENOME-WIDE ASSOCIATION STUDIES FOR ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (R01)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

### **Description:**

The National Institute of Arthritis and Musculoskeletal and Skin Diseases invites applications for its identification and analysis of causal variants: follow-up on genome-wide association studies for arthritis and musculoskeletal and skin diseases grants.

This R01 funding opportunity announcement encourages applications that aim to characterise the genetic variations in human genomic regions that have been putatively associated with complex diseases relevant to the NIAMS mission. The purpose is to accelerate the discovery of causal genes and variants that influence the risk for disease; and conduct follow-up studies of particular genetic variants to gain novel insights into the functions of these variants and the mechanisms by which they may contribute to disease. Genomic regions of interest are primarily those identified by genome-wide association studies (GWAS) although other types of evidence may also inform the rationale for a given study. These studies are essential for the translation of initial GWAS finding into biological insights, and ultimately important for improving our understanding of the molecular mechanisms of disease that could lead to predictive, diagnostic, and therapeutic advances.

This FOA uses the R01 research project grant mechanism and runs in parallel with a FOA of similar scientific scope, PAR-12-230, that encourages applications under the R21 exploratory/developmental grant mechanism.

Direct costs are limited to US\$350,000 per year, for a maximum period of four years. Application budgets need to reflect actual needs of the proposed project. Eligible applicants include domestic and foreign non-

profit or for-profit organisations and public or private institutions. PAR 12-236 (replaces PAR-09-135)

**Closing date: 20 Nov 12**

**Deadline information: Applications due 20 November 2012, 20 May 2013 and 20 November 2013, by 5pm local time of applicant organisation.**

**Posted date: 12 Jul 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$1,400,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-236.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-236>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Musculoskeletal System, Arthritis, Rheumatic Diseases, Skin Diseases, Aetiology, Mapping, Genetic, Medical Genetics, Rheumatology, DNA Mapping, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Biological Sciences (RAE Unit 14), Genomics, Proteomics, Clinical Laboratory Science, Hospital-based Clinical Subject, Translational Medicine, Genetic Diseases

### **Contact Details**

-----  
Division of Skin and Rheumatic Diseases  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
One Democracy Plaza, Suite 800  
6701 Democracy Blvd.

Bethesda, MD 20892-4872  
Tel: +1 301 594 5032  
Fax: +1 301 480 1284

Email: [wangy1@mail.nih.gov](mailto:wangy1@mail.nih.gov)

---

**B**ASIC CANCER RESEARCH IN CANCER HEALTH DISPARITIES (U01)  
*NIH: National Cancer Institute*

**Description:**

The National Cancer Institute invites applications for its grants program for basic cancer research in cancer health disparities (U01). This U01 funding opportunity announcement will support basic research into the biological causes and mechanisms of cancer health disparities. Awards will support innovative studies in biological and genetic causes of cancer health disparities, including development and testing of new methodologies and models, secondary data analyses, and mechanistic studies, that investigate identified biological factors associated with cancer disparities. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can provide resources and tools, such as biospecimens, cell lines and methods necessary to conduct basic research in this area.

This FOA will use the NIH cooperative agreement (U01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-094, which solicits applications under the exploratory/developmental (R21) research grant award mechanism. Applicants may request a project period of up to five years and a budget for direct costs up to \$250,000 per year. Applications will be accepted from domestic and foreign for-profit or non-profit PAR-12-095 (replaces PAR-09-161)

**Closing date:** 20 Nov 12

**Deadline information:** Deadline: 5pm local time of applicant organization, 20 June and 20 November annually.

**Posted date:** 03 Feb 12

**Award type:** Directed grants to institutions, research groups etc

**Award amount max:** \$1,250,000

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-095.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-12-095>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Cancer Biology, Cancer & Carcinogenesis, Tumour Immunology, Public Health, Disease Prevention, Molecular Genetics, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Other Studies and Professions Allied to Medicine (RAE Unit 11), Clinical Laboratory Science, Health Disparities, Community-based Clinical Subjects, Hospital-based Clinical Subject, Other Studies and Professions Allied to Medicine

**Contact Details**

-----  
Division of Cancer Biology  
National Cancer Institute

Executive Plaza North, Room 5014  
6130 Executive Boulevard, MSC 7344  
Bethesda, MD 20892-7344

Tel: +1 301 496 1951  
Fax: +1 301 496 2025  
Email: [PD93U@nih.gov](mailto:PD93U@nih.gov)

---

**EXPLORATORY/DEVELOPMENTAL GRANTS PROGRAM FOR BASIC CANCER RESEARCH IN CANCER HEALTH DISPARITIES (R21)**  
NIH: National Cancer Institute

**Description:**

The National Cancer Institute invites applications for its exploratory/developmental grants program for basic cancer research in cancer health disparities (R21). This R21 funding opportunity announcement will support basic research studies into the biological causes and mechanisms of cancer health disparities. Awards will support pilot and feasibility studies, development and testing of new methodologies, secondary data analyses, and innovative mechanistic studies that investigate biological or genetic bases of cancer health disparities. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research and to provide resources for those investigators that may need additional support on their path to successfully compete for R01 funding in basic mechanistic research in understanding cancer health disparities.

This FOA will utilise the NIH exploratory/developmental (R21) research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-095, which solicits applications under the research project (U01) cooperative agreement mechanism.

Application budgets are limited to \$275,000 over a two-year project period, and no more than \$200,000 may be requested in any single year. Domestic and foreign for-profit and

non-profit organisations and public or private institutions are eligible to apply. PAR-12-094 (replaces PAR-09-160)

**Closing date: 20 Nov 12**

**Deadline information: Deadline: 5pm local time of applicant organization, 20 June and 20 November annually. Deadlines on: 20 November 2012, 20 June 2013, and repeated annually.**

**Posted date: 03 Feb 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-094.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-094>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Cancer Biology, Cancer & Carcinogenesis, Tumour Immunology, Public Health, Disease Prevention, Molecular Genetics, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Other Studies and Professions Allied to Medicine (RAE Unit 11), Clinical Laboratory Science, Health Disparities, Community-based Clinical Subjects,



Hospital-based Clinical Subject, Other  
Studies and Professions Allied to Medicine

### Contact Details

-----  
Division of Cancer Biology  
NCI

Executive Plaza North, Room 5014  
6130 Executive Boulevard, MSC 7344  
Bethesda, MD 20892-7344  
Tel: +1 301 496 1951  
Fax: +1 301 496 2025  
Email: [PD93U@nih.gov](mailto:PD93U@nih.gov)

---

## **I** DENTIFICATION AND ANALYSIS OF CAUSAL VARIANTS: FOLLOW-UP ON G ENOME-WIDE ASSOCIATION STUDIES FOR ARTHRITIS AND M USCULOSKELETAL AND SKIN DISEASES (R21)

*NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases*

### Description:

The National Institute of Arthritis and Musculoskeletal and Skin Diseases invites applications for its identification and analysis of causal variants: follow-up on genome-wide association studies for arthritis and musculoskeletal and skin diseases grants.

This R21 funding opportunity announcement encourages applications that are exploratory/developmental and highly innovative in nature, and aim to characterise the genetic variations in human genomic regions that have been putatively associated with complex diseases relevant to the NIAMS mission. The purpose is to accelerate the discovery of causal genes and variants that influence the risk for disease; and conduct follow-up studies of particular genetic variants to gain novel insights into the functions of these variants and the mechanisms by which they may contribute to disease. Genomic regions of interest are primarily those identified by genome-wide association studies (GWAS) although other types of evidence may also inform the rationale for a given study. These studies are essential for the translation of initial GWAS finding into biological insights, and ultimately important for improving our understanding of the molecular mechanisms

of disease that could lead to predictive, diagnostic, and therapeutic advances.

This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with a FOA of similar scientific scope, PAR-12-236, that encourages applications under the R01 research project grant mechanism.

Direct costs are limited to US\$275,000 for a period of two years, with no more than US\$200,000 allowed in any single year. The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR 12-230

**Closing date: 20 Nov 12**

**Deadline information: Applications due 20 November 2012, 20 May 2013 and 20 November 2013, by 5pm local time of applicant organisation.**

**Posted date: 12 Jul 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-236.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-236>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Musculoskeletal System, Arthritis, Rheumatic Diseases, Skin Diseases, Aetiology, Mapping, Genetic, Medical Genetics, Rheumatology, DNA Mapping, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical

Subjects (RAE Unit 3), Biological Sciences (RAE Unit 14), Genomics, Proteomics, Clinical Laboratory Science, Hospital-based Clinical Subject, Translational Medicine, Genetic Diseases

**Contact Details**

Division of Skin and Rheumatic Diseases  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
One Democracy Plaza, Suite 800  
6701 Democracy Blvd.  
Bethesda, MD 20892-4872  
**Tel:** +1 301 594 5032  
**Fax:** +1 301 480 1284  
**Email:** [wangy1@mail.nih.gov](mailto:wangy1@mail.nih.gov)

---

**DEVELOPMENT AND APPLICATION OF SYSTEMS APPROACHES FOR ANALYSING THE IMPACT OF GENOMIC VARIATION ON TISSUE TRANSCRIPTOMES (R01)**

*NIH: Office of the Director*

**Description:**

The National Institutes of Health's office of strategic coordination invites applications for its development and application of systems approaches for analysing the impact of genomic variation on tissue transcriptomes (R01) programme. The purpose of this R01 funding opportunity announcement is to develop and apply statistical methods and systems approaches to make maximal use of genotype-tissue expression data. The goal of the GTEx project is to develop a data and sample resource to study the relationship between genetic variation and gene expression across multiple human reference tissues, in order to identify effect on the tissue transcriptome. Genetic variants may be based on single-nucleotide polymorphism genotyping as well as copy number variants, small insertions or deletions, or epigenetic modifications. Examples of interest in this FOA are cis- and trans-acting variants in

determining quantitative trait loci, tissue specific transcripts, identifying common transcripts in tissue clusters and identifying allele-specific bias. Novel approaches to examine other types of transcriptome effects are encouraged. Statistical methods based on single gene, regional chromosome architecture, gene-gene interactions, gene-networks and broader systems approaches are also encouraged.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

This FOA will be administered by the National Institute of Mental Health. NIH intends to commit approximately US\$3.3 million in total costs to fund up to eight awards in fiscal year 2013. Application budgets are not limited, but must reflect the

actual needs of the project. The maximum project period is five years. RFA-RM-12-019

**Closing date: 21 Nov 12**

**Deadline information: Applications due by 5pm, proposer's local time.**

**Posted date: 08 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Innovation grants**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-019.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=RFA-RM-12-019>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Systems Theory, Connective Tissue, Mapping, Genetic, Nucleic Acid Sequencing, Recombinant DNA, Tissue Culture, DNA &

RNA Hybrids, DNA Mapping, DNA Replication, DNA Sequencing, Evolutionary Variation, Statistics, Human Genome, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Statistics and Operational Research (RAE Unit 24), Electrical and Electronic Engineering (RAE Unit 29), Genomics, Clinical Laboratory Science, Community-based Clinical Subjects, Other Studies and Professions Allied to Medicine, Life Science (Bioscience), Epigenetics, Tissue

**Contact Details**

-----  
Division of Neuroscience and Basic Behavioural Science  
NIMH  
6001 Executive Boulevard, Room 7200, MSC 9643  
Bethesda, MD 20892-9643  
Tel: +1 301 443 6653  
Email: [patrick.bender@nih.gov](mailto:patrick.bender@nih.gov)



## **PREVENTION OF HIV TRANSMISSION/ACQUISITION THROUGH A BETTER UNDERSTANDING OF REPRODUCTIVE HEALTH (R01)** *NIH: National Institute of Child Health and Human Development*

### **Description:**

The National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Disease invite applications for their prevention of HIV transmission/acquisition through a better understanding of reproductive health (R01) grants. This R01 funding opportunity announcement seeks to further scientific understanding of HIV acquisition or transmission by increasing knowledge

regarding the intersection between reproductive health and HIV prevention.

The emphasis of the FOA is to encourage comprehensive behavioural-biomedical approaches that can lead to new insights in HIV prevention research. This initiative seeks to change the prevention effort from focusing on the discrete development of specific vaginal (or oral) formulation compounds towards looking at the complexities and interactions between HIV acquisition or

transmission and reproductive biology and behaviour. The FOA is segmented into three general areas:

- behavioural studies in HIV-infected and at-risk men, women and couples that may impact on HIV acquisition or transmission;
- biomedical-behavioural studies in reproductive biology that may impact on HIV acquisition or transmission;
- basic science research on endogenous and exogenous hormones and their effect on HIV acquisition or transmission.

This FOA will use the R01 research project grant mechanism and runs in parallel with an

FOA of identical scientific scope, RFA-HD-13-009, that encourages applications under the R03 small grant mechanism.

NICHD intends to commit approximately US\$2 million in fiscal year 2013 to fund four to six awards. Application budgets are limited to US\$350,000 per year. The total project period may not exceed five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. RFA-HD-13-008 (replaces RFA-HD-12-198).

**Closing date: 29 Nov 12**

**Deadline information: Letters of intent due 29 October; full applications due 29 November 2012, by 5pm local time of applicant organisation.**

**Posted date: 12 Sep 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$1,750,000**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-13-008.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-HD-13-008>

### Eligibility profile

-----  
Nationality of applicant institution: Any

### Disciplines

-----  
Transmission of HIV/AIDS, Human Reproduction & Fertility, Sexuality & Sex Roles, Behaviour & Health, Reproductive Endocrinology, Sexually Transmitted Diseases, Disease Prevention, Contraceptives, Drug Design, Hormones, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Psychology (RAE Unit 13), Sociology (RAE Unit 42), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, HIV/AIDS, Social Aspects

### Contact Details

-----  
Center for Population Research  
NICHD  
6100 Executive Boulevard, Room 8B13, MSC 7510  
Bethesda, MD 20892  
Tel: +1 301 435 6991  
Fax: +1 301 480 1972  
Email: [reichelp@mail.nih.gov](mailto:reichelp@mail.nih.gov)

## **P**REVENTION OF HIV TRANSMISSION/ACQUISITION THROUGH A BETTER UNDERSTANDING OF REPRODUCTIVE HEALTH (R03) NIH: National Institute of Child Health and Human Development

### **Description:**

The National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Disease invite applications for their prevention of HIV transmission/acquisition through a better understanding of reproductive health (R03) grants. This R03 funding opportunity announcement seeks to further scientific understanding of HIV acquisition or transmission by increasing knowledge regarding the intersection between reproductive health and HIV prevention.

The emphasis of the FOA is to encourage comprehensive behavioural-biomedical approaches that can lead to new insights in HIV prevention research. This initiative seeks to change the prevention effort from focusing on the discrete development of specific vaginal (or oral) formulation compounds towards looking at the complexities and interactions between HIV acquisition or transmission and reproductive biology and behaviour. The FOA is segmented into three general areas:

- behavioural studies in HIV-infected and at-risk men, women and couples that may impact on HIV acquisition or transmission;
- biomedical-behavioural studies in reproductive biology that may impact on HIV acquisition or transmission;
- basic science research on endogenous and exogenous hormones and their effect on HIV acquisition or transmission.

This FOA will use the R03 small grant programme mechanism and runs in parallel with an FOA of identical scientific scope, RFA-HD-13-008, that encourages applications under the R01 research project grant mechanism.

NICHD intends to commit approximately US\$600,000 in fiscal year 2013 to fund six to eight awards. Application budgets are limited to US\$50,000 per year. The total project period may not exceed two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. RFA-HD-13-009 (replaces RFA-HD-12-199).

**Closing date: 29 Nov 12**

**Deadline information: Letters of intent due 29 October; full applications due 29 November 2012, by 5pm local time of applicant organisation.**

**Posted date: 12 Sep 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-13-009.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-HD-13-009>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Transmission of HIV/AIDS, Human Reproduction & Fertility, Sexuality & Sex Roles, Behaviour & Health, Reproductive Endocrinology, Sexually Transmitted Diseases, Disease Prevention, Contraceptives, Drug Design, Hormones, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Psychology (RAE Unit 13), Sociology (RAE



Unit 42), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, HIV/AIDS, Social Aspects

**Contact Details**

-----  
Center for Population Research

NICHD  
6100 Executive Boulevard, Room 8B13, MSC 7510  
Bethesda, MD 20892  
Tel: +1 301 435 6991  
Fax: +1 301 480 1972  
Email: [reichelp@mail.nih.gov](mailto:reichelp@mail.nih.gov)



**EXPANSION OF SYMPTOMS OF LOWER URINARY TRACT DYSFUNCTION RESEARCH NETWORK (U01)**

*NIH: National Institute of Diabetes and Digestive and Kidney Diseases*

**Description:**

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its expansion of symptoms of lower urinary tract dysfunction research network (U01) grants. This U01 funding opportunity announcement invites added sites to join the current symptoms of lower urinary tract dysfunction research network investigators. Research seeks to expand on validating symptom-based instruments to measure early, late, transient and persistent

symptoms both in males and females, and to better define the phenotypes of men and women with symptoms of lower urinary tract dysfunction. The key responsibilities of the added research sites and the expanded data coordinating centre will be to adopt the study protocols developed by LURN investigators, validate the developed patient reported outcome measures, recruit study participants and conduct extensive characterisation of them.

NIDDK intends to commit US\$1.87 million in fiscal year 2013 to fund four to five awards. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private

institutions are eligible to apply. RFA-DK-12-017.

**Closing date: 29 Nov 12**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 03 Sep 12**

**Award type: Directed grants to institutions, research groups etc, Research centres, Networking/collaboration**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-12-017.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-DK-12-017>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Biomedical, Medical Sciences, Health, Disease Entities & Medical Problems & Behaviour, Incontinence, Clinical Laboratory Sciences (RAE Unit 1), Clinical Laboratory Science



**Contact Details**

-----  
Division of Kidney, Urologic and  
Hematologic Diseases  
NIH  
2 Democracy Plaza, Room 627

6707 Democracy Boulevard, MSC 5458  
Bethesda, MD 20892  
Tel: +1 301 594 7717  
Fax: +1 301 480 3510  
Email: [kirkaliz@mail.nih.gov](mailto:kirkaliz@mail.nih.gov)



## DECEMBER 2012

### **A** NCILLARY STUDIES TO LARGE ONGOING CLINICAL PROJECTS (R01) NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

#### **Description:**

The National Institute of Arthritis and Musculoskeletal and Skin Diseases invites applications for its ancillary studies to large ongoing clinical projects (R01) programme. This R01 funding opportunity announcement solicits applications that propose to conduct time-sensitive ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, large, ongoing clinical projects. The ongoing parent project can be a large clinical trial or observational study, or a disease registry that can provide a sufficient cohort of well-characterised patients, infrastructure, data, and biological samples. Each application must include a timeline to demonstrate that the parent project has adequate time left to accommodate the proposed ancillary study. In addition, it must justify the time-sensitive nature of the ancillary study and the need for an expedited review and award process. It must also document permission from the parent project to use the patient cohorts, data, and biological materials. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximise the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects. Successful projects will enhance the scientific context and value of the parent projects, improve understanding of a disease or organ system and identify novel targets for diagnosis, treatment and prevention of disease.

This FOA will utilise the R01 award mechanism and runs in parallel with a FOA of identical scientific scope, RFA-AR-13-011, that encourages applications under the R21

award mechanism. The NIAMS expects to commit approximately US\$1.5 million in total costs in FY2013 to support a total of four to six new awards combined under both mechanisms. Budgets for direct costs of up to US\$250,000 per year and a project duration for up to four years may be requested. Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. RFA-AR-13-010 (replaces RFA-AR-11-012).

**Closing date: 03 Dec 12**

**Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 3 December 2012, 16 April 2013.**

**Posted date: 23 Jul 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$1,000,000**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-13-010.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-AR-13-010>

#### **Eligibility profile**

-----  
 Nationality of applicant institution: Any

#### **Disciplines**

-----  
 Musculoskeletal System, Arthritis, Muscle Disorders, Rheumatic Diseases, Skeletal Diseases, Skin Diseases, Biomedical Research Training, Dermatology, Rheumatology,

Clinical Laboratory Sciences (RAE Unit 1),  
Clinical Laboratory Science

**Contact Details**

-----  
Division of Skin and Rheumatic Diseases

National Institute of Arthritis and  
Musculoskeletal and Skin Diseases  
6701 Democracy Boulevard, Suite 800  
Bethesda, MD 20892  
Tel: +1 301 451 5888  
Email: [ricardo.cibotti@nih.gov](mailto:ricardo.cibotti@nih.gov)



**A** NCILLARY STUDIES TO LARGE ONGOING CLINICAL PROJECTS (R21)  
*NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases*

**Description:**

The National Institute of Arthritis and Musculoskeletal and Skin Diseases invites applications for its ancillary studies to large ongoing clinical projects (R21) programme.

This R21 funding opportunity announcement solicits applications that propose to conduct time-sensitive ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, large, ongoing clinical projects. The ongoing parent project can be a large clinical trial or observational study, or a disease registry that can provide a sufficient cohort of well-characterised patients, infrastructure, data, and biological samples. Each application must include a timeline to demonstrate that the parent project has adequate time left to accommodate the proposed ancillary study. In addition, it must justify the time-sensitive nature of the ancillary study and the need for an expedited review and award process. It must also document permission from the parent project to use the patient cohorts, data, and biological materials. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximise the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects. Successful projects will enhance the scientific context and value of the parent projects, improve understanding

of a disease or organ system and identify novel targets for diagnosis, treatment and prevention of disease.

This FOA will utilise the R21 award mechanism and runs in parallel with a FOA of identical scientific scope, RFA-AR-13-010, that encourages applications under the R01 award mechanism. The NIAMS expects to commit approximately US\$1.5 million in total costs in FY2013 to support a total of four to six new awards combined under both mechanisms. The total project period may not exceed two years. Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. RFA-AR-13-011 (replaces RFA-AR-11-013).

**Closing date: 03 Dec 12**

**Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 3 December 2012, 16 April 2013.**

**Posted date: 23 Jul 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-13-011.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-AR-13-011>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Musculoskeletal System, Arthritis, Muscle Disorders, Rheumatic Diseases, Skeletal Diseases, Skin Diseases, Biomedical Research

Training, Dermatology, Rheumatology, Clinical Laboratory Sciences (RAE Unit 1), Clinical Laboratory Science

**Contact Details**

Division of Skin and Rheumatic Diseases  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
6701 Democracy Boulevard, Suite 800  
Bethesda, MD 20892  
Tel: +1 301 451 5888  
Email: [ricardo.cibotti@nih.gov](mailto:ricardo.cibotti@nih.gov)



**NEURONEXT CLINICAL TRIALS (U01)**  
*NIH: National Institute of Neurological Disorders and Stroke*

**Description:**

The National Institute of Neurological Disorders and Stroke invites applications for its NeuroNEXT clinical trials U01 grants. This encourages applications for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy in the treatment of neurologic disease. Applications for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests. Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently

implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.

This FOA uses the research project - cooperative agreements U01 funding mechanism and runs parallel to FOAs of similar scientific scope PAR-11-344 that uses the resource access award X01 funding mechanism and PAR-11-345 that uses the small business innovation research (SBIR) cooperative agreement - phase II and fast-track U44 funding mechanism, however this is available for US based candidates only.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum request cannot exceed five years but the actual funded project period is dependent on reaching specific

milestones as described in this FOA. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Applications are accepted from non-US entities, foreign components of US based organisations and components of US organizations, but they will have to work with the US-based NeuroNEXT infrastructure.

PAR-11-343

**Closing date: 03 Dec 12**

**Deadline information: Deadline time: 5pm local time of applicant organisation**

**Posted date: 22 Sep 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-343.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-343>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Disease Prevention, Clinical Trial, Biochemical Markers, Biological Markers, Research Resources (Health & Safety & Medical), Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Hospital-based Clinical Subject

**Contact Details**

-----  
Tel: +1 301 496 9135

Email: [mcneilde@ninds.nih.gov](mailto:mcneilde@ninds.nih.gov)

## **G**LOBAL PARTNERSHIPS FOR SOCIAL SCIENCE AIDS RESEARCH (R24)

*NIH: National Institute of Child Health and Human Development*

### **Description:**

The National Institute of Child Health and Human Development invites applications for the global partnerships for social science Aids research programme. This R24 funding opportunity announcement calls for collaborative applications between institutions in the US and other developed countries and research institutions in developing countries. The goal of this FOA is to strengthen the research infrastructure of local institutions in developing countries and provide support for a small portfolio of high impact social or behavioural science research on the prevention, care and treatment of HIV/Aids. Activities supported under this

FOA should be led by local social and behavioural scientists in partnership with scientists from developed countries. The research projects and enhanced research infrastructure support should be designed to foster the emergence of local scientists as recognised leaders in behavioural and social sciences research on HIV/Aids. Applications will be accepted for work in any country in Asia, Latin America or central and eastern Europe that reports an HIV prevalence higher than 1 per cent of the adult population for the country overall or in a specific geographic or population area.



NICHD intends to commit US\$1 million in fiscal year 2013. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible organisations include domestic and foreign for-profit and non-profit, public or private organisations. RFA-HD-13-012 (replaces RFA-HD-06-007).

**Closing date: 07 Dec 12**

**Deadline information: Letter of intent due 7 November 2012; full applications due 7 December 2012.**

**Posted date: 07 Aug 12**

**Award type: Directed grants to institutions, research groups etc, Development (Africa/Caribbean), Networking/collaboration, Research centres**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-13-012.html>

**Application form:**

<http://grants.nih.gov/grants/funding/phs398/phs398.html>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

-----  
 Developing & Underdeveloped Nations, Behavioural Studies & Social Problems, Transmission of HIV/AIDS, Sexual Behaviour, Social Services, Medical Sociology, Behaviour & Health, AIDS, Behavioural Medicine, HIV Infection, Social & Economic Environment (Medical), Access to Health Care, Child & Maternal Health, Health Care Quality & Effectiveness, Public Health, Disease Prevention, Preventive Medicine, Treatment, Medical, Community-based Clinical Subjects (RAE Unit 2), Psychology (RAE Unit 13), Sociology (RAE Unit 42), Health Disparities, Community-based Clinical Subjects

**Contact Details**

-----  
 Demographic and Behavioral Sciences Branch  
 NICHD  
 6100 Executive Boulevard  
 Room 8B07G, MSC 7510  
 Bethesda, MD 20892-7510  
 Tel: +1 301 435 6981  
 Email: [newcomes@mail.nih.gov](mailto:newcomes@mail.nih.gov)



**STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01)**  
 NIH: National Institute on Drug Abuse

**Description:**

The National Institute on Drug Abuse invites applications for its strategic alliances for medications development to treat substance use disorders (R01). The purpose of this R01 funding opportunity announcement is to support efforts to develop medications for the treatment of substance use disorders by leveraging the strengths of two or more organisations toward a common goal of

medications development. NIDA anticipates that strategic alliances will increase the pace at which such medications move through the drug development process. Project aims can range from the development of a new molecular entity to the expansion of an existing medication's clinical indication, but each project should have a defined entry and exit point with the objective of advancement in the approval process.

Targeted organisation types include foreign and domestic for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations and small businesses.

NIDA intends to commit US\$6 million in fiscal year 2013 to fund two to four awards. Budgets for direct costs may be up to US\$2 million per year. The maximum project period is three years.

**Closing date: 07 Dec 12**

**Deadline information: Deadlines: 7 August, 7 December 2012; 17 July, 4 December 2013; 24 March and 4 December 2014.**

**Posted date: 22 Mar 12**

**Award type: Directed grants to institutions, research groups etc, Academic-Industry links, Clinical trials, Networking/collaboration**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAS-12-122.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAS-12-122>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Drug & Substance Abuse, Pharmacology, Pharmacy, Drug Delivery Systems, Pharmaceuticals, Drug Design, Clinical Laboratory Sciences (RAE Unit 1), Pharmacology (RAE Unit 8), Pharmacy (RAE Unit 9), Clinical Laboratory Science, Medication Studies

**Contact Details**

Division of Pharmacotherapies and Medical Consequences of Drug Abuse

NIDA

6001 Executive Boulevard

Bethesda, MD 20892-9561

Tel: +1 301 443 8096

Email: [jb168r@nih.gov](mailto:jb168r@nih.gov)

## **M** ULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R21) NIH: National Institute on Aging

### **Description:**

A total of nine institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/Aids and ageing (R21) programme. This R21 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or biobehavioural or social factors associated with HIV/Aids research in the context of ageing or in older adults. Research approaches of interest include clinical

translational, observational and intervention studies in domestic and international settings.

This FOA will use the R21 exploratory/developmental research grant award and runs in parallel with two FOAs of identical scope, PAR-12-175, which uses the R01 research project grant mechanism and PAR-12-176, which uses the R03 small grant mechanism.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-12-174.

**Closing date:** 07 Dec 12

**Deadline information: Deadlines on:** 7 August 2012, 7 December 2012, 9 April 2013, 7 August 2013, 6 December 2013, 9 April 2014, 7 August 2014, 9 December 2014, 7 April 2015.

**Posted date:** 25 Apr 12

**Award type:** Directed grants to institutions, research groups etc

**Award amount max:** \$275,000

**Award amount min:** -

**Award budget total:** -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-174.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-174>

**Eligibility profile**

Nationality of applicant institution: Any

### Disciplines

-----  
Transmission of HIV/AIDS, Ageing & Gerontology, Disease Entities & Medical Problems & Behaviour, AIDS, Breast Cancer, Cancer & Carcinogenesis, HIV Infection, Prostate Cancer, Intervention, Types of (Health & Safety & Medical), Treatment, Medical, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Leukaemia, Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

### Contact Details

-----  
NIA  
7201 Wisconsin Avenue  
Bethesda, MD 20892  
Tel: +1 301 496 6761  
Email: [basil.eldadah@nih.gov](mailto:basil.eldadah@nih.gov)

## **M**ULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R01)

NIH: National Institute on Aging

### **Description:**

A total of eleven institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/Aids and ageing (R01) programme. This R01 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or biobehavioural or social factors associated with HIV/Aids research in the context of ageing or in older adults. Research

approaches of interest include clinical translational, observational and intervention studies in domestic and international settings.

This FOA will use the R01 research project grant and runs in parallel with two FOAs of identical scope, PAR-12-174, which uses the R21 exploratory/developmental research grant mechanism and PAR-12-176, which uses the R03 small grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-12-175.

**Closing date: 07 Dec 12**

**Deadline information: Deadlines on: 7 August 2012, 7 December 2012, 9 April 2013, 7 August 2013, 6 December 2013, 9 April 2014, 7 August 2014, 9 December 2014, 7 April 2015.**

**Posted date: 25 Apr 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-175.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-12-175>

**Eligibility profile**

-----

Nationality of applicant institution: Any

**Disciplines**

-----

Transmission of HIV/AIDS, Ageing & Gerontology, Disease Entities & Medical Problems & Behaviour, AIDS, Breast Cancer, Cancer & Carcinogenesis, HIV Infection, Prostate Cancer, Intervention, Types of (Health & Safety & Medical), Treatment, Medical, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Leukaemia, Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

**Contact Details**

-----

NIA

7201 Wisconsin Avenue

Bethesda, MD 20892

Tel: +1 301 496 6761

Email: [basil.eldadah@nih.gov](mailto:basil.eldadah@nih.gov)

## **M** ULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R03) NIH: National Institute on Aging

### **Description:**

A total of six institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/Aids and ageing (R03) programme. This R03 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or biobehavioural or social factors associated with HIV/Aids research in the context of ageing or in older adults. Research

approaches of interest include clinical translational, observational and intervention studies in domestic and international settings.

This FOA will use the R03 small grant mechanism and runs in parallel with two FOAs of identical scope, PAR-12-174, which uses the R21 exploratory/developmental research grant mechanism and PAR-12-175, which uses the R03 research project grant.

Application budgets are limited to US\$100,000 over a two-year project period, with no more than US\$50,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-12-176.

**Closing date:** 07 Dec 12

**Deadline information: Deadlines on:** 7 August 2012, 7 December 2012, 9 April 2013, 7 August 2013, 6 December 2013, 9 April 2014, 7 August 2014, 9 December 2014, 7 April 2015.

**Posted date:** 25 Apr 12

**Award type:** Directed grants to institutions, research groups etc

**Award amount max:** \$100,000

**Award amount min:** -

**Award budget total:** -

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-176.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-176>

### Eligibility profile

Nationality of applicant institution: Any

### Disciplines

Transmission of HIV/AIDS, Ageing & Gerontology, Disease Entities & Medical Problems & Behaviour, AIDS, Breast Cancer, Cancer & Carcinogenesis, HIV Infection, Prostate Cancer, Intervention, Types of (Health & Safety & Medical), Treatment, Medical, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Leukaemia, Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

### Contact Details

NIA

7201 Wisconsin Avenue

Bethesda, MD 20892

Tel: +1 301 496 6761

Email: [basil.eldadah@nih.gov](mailto:basil.eldadah@nih.gov)

## **C**OHORT STUDIES OF HIV/AIDS AND SUBSTANCE USE (U01)

*NIH: National Institute on Drug Abuse*

### Description:

The National Institute on Drug Abuse invites applications for its cohort studies of HIV/Aids and substance abuse (R01) grants. This R01 funding opportunity announcement supports longitudinal cohort studies to address emerging or high-priority research on HIV/Aids and substance abuse. This FOA will support the development and maintenance of new cohorts or the expansion

of existing cohorts to address the natural and treated history of HIV infection in at-risk populations where substance abuse is a central factor. The intent is to provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV infection, prevention and treatment in the context of substance abuse, as well as to foster the creativity and



efficiency of investigator-initiated research goals.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-12-222.

**Closing date: 11 Dec 12**

**Deadline information: Applications are due by 5pm local time of applicant organisation.**

**Posted date: 02 Jul 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-222.html>

**Application form:**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-222.html>

### Eligibility profile

Nationality of applicant institution: Any

### Disciplines

Drug & Substance Abuse, Transmission of HIV/AIDS, At Risk Persons, AIDS, HIV Infection, Infectious Diseases & Agents, Disease Prevention, Treatment, Medical, Clinical Laboratory Sciences (RAE Unit 1), Clinical Laboratory Science

### Contact Details

Division of Pharmacotherapies and Medical Consequences of Drug Abuse

NIDA

6001 Executive Boulevard, Room 4137, MSC 9551

Bethesda, MD 20892-95951

Tel: +1 301 443 2159

Fax: +1 301 443 2599

Email: [jk98p@nih.gov](mailto:jk98p@nih.gov)



## **C**ANCER PREVENTION RESEARCH SMALL GRANT PROGRAM (R03) *NIH: National Cancer Institute*

### **Description:**

The National Cancer Institute invites applications for its cancer prevention research small grant program. This R03 funding opportunity announcement welcomes small and time-limited projects pertinent to the development of cancer chemoprevention agents, biomarkers for early cancer detection, cancer-related nutrition science, or clinical prevention studies that focus on specific target organs. Proposed projects may involve basic animal and translational research and human

subjects-oriented research. However, treatment related quality of life population based studies, as well as projects focused on cancer etiology, metastasis, animal model development, or treatment will not be appropriate for this FOA. New, as well as established, investigators in relevant fields and disciplines are encouraged to apply for these small grants to test the feasibility of innovative ideas or carry out pilot studies. Ultimately, these small grants are expected to facilitate the development of full research projects grants.

This solicitation will use the NIH R03 small grants program award mechanism. Budgets for direct costs of up to \$50,000 per year and a project duration of up to two years may be requested for a maximum of \$100,000 direct costs over a two-year project period. Applications may be submitted by domestic and foreign for-profit or non-profit organizations and public or private institutions. PAR-11-079 (replaces PAR-08-055)

**Closing date: 14 Dec 12**

**Deadline information: Deadlines on: 18 March 2011, 21 July 2011, 16 December 2011, 15 February 2012, 18 July 2012, 14 December 2012, 15 February 2013, 19 July 2013, 16 December 2013.**

**Posted date: 15 Dec 10**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-079.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-079>

## Eligibility profile

Nationality of applicant institution: Any

## Disciplines

Medical & Diagnostic Imaging, Cancer Biology, Nutrition & Dietetics, Pharmacology, Cancer & Carcinogenesis, Chemopreventive Agents, Chemoprevention, Disease Prevention, Preventive Medicine, Biochemical Markers, Biological Markers, Oncology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Other Studies and Professions Allied to Medicine (RAE Unit 11), Clinical Laboratory Science, Other Studies and Professions Allied to Medicine, Translational Medicine

## Contact Details

NCI

6130 Executive Boulevard, EPN

Room 3137, MSC 7362

Bethesda, MD 20892-7362

Tel: +1 301 435 0584

Email: [LynnS@mail.nih.gov](mailto:LynnS@mail.nih.gov)

## LIMITED COMPETITION: FRAMEWORK PROGRAMS FOR GLOBAL HEALTH INNOVATION (D43)

NIH: Fogarty International Center

### Description:

The Fogarty International Center invites applications for its limited competition: framework programs for global health innovation awards. The purpose of this funding opportunity announcement is to provide support for the development of broadly interdisciplinary training programs in global health directed towards

encouraging innovation in products, processes and policies. Training projects should identify critical health needs in low- and middle-income countries that can be addressed through innovation, and carry out the scientific research necessary to develop, validate and test their concepts. To increase the translation of research findings into realized health benefits, project design

should include settings in LMICs, particularly regarding increased effectiveness, affordability, accessibility, ease of use or delivery or scalability. This FOA emphasizes hands-on, problem-solving and collaborative approaches and allows US and LMIC trainees to be trained together. By engaging multiple entities within and among institutions, the proposed programs should also build institutional capacity for interdisciplinary training in global health, stimulate new collaborations, and increase the pipeline of researchers from a wide variety of fields who engage in global health research.

Trainees should be at postdoctoral level or have attained a terminal degree in their fields. Applicants may request total costs of up to \$350,000 per year. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Non-domestic entities are restricted to institutions in "low- and middle-income" countries as defined by the World Bank according to Gross National Income per capita as "low-income," "lower-middle-income," and "upper-middle-income".

**Closing date: 14 Dec 12**

**Deadline information: Deadline: letters of intent due November 16, 2011 and November 15, 2012; full applications due 5pm applicant's local time, December 15, 2011 and December 14, 2012.**

**Posted date: 17 Oct 11**

**Award type: Development (Africa/Caribbean), Directed grants to institutions, research groups etc**

**Award amount max: \$350,000**

**Award amount min: -**

**Award budget total: -**

#### **Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-003.html>

#### **Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-003>

#### **Eligibility profile**

Nationality of applicant institution: Congo, Senegal, Uzbekistan, Vietnam, Yemen, Kosovo, Armenia, Bolivia, Bhutan, Belize, Côte d'Ivoire, Cameroon, Cape Verde, Djibouti, Egypt, Micronesia, Federated States of, Georgia, Guatemala, Guyana, Honduras, Indonesia, India, Iraq, Kiribati, Sri Lanka, Lesotho, Morocco, Moldova, Republic of, Marshall Islands, Mongolia, Nigeria, Nicaragua, Papua New Guinea, Philippines, Pakistan, Palestinian Territory, Occupied, Paraguay, Sudan, Sao Tome and Principe, El Salvador, Syrian Arab Republic, Swaziland, Timor-Leste, Tonga, Ukraine, Vanuatu, Samoa, Albania, Fiji, Ghana, Lao People's Democratic Republic, Solomon Islands, Zambia, South Sudan, Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Nationality of applicant institution: United States

#### **Disciplines**

Health Care, Health Care Policy, International Health, Social Policy and Administration (RAE Unit 40)

#### **Contact Details**

Fogarty International Center  
National Institutes of Health  
Building 31  
31 Center Drive, MSC 2220  
Bethesda, MD 20892  
Tel: +1 301 402 9591  
Email: [katz@mail.nih.gov](mailto:katz@mail.nih.gov)

## **PLANNING GRANTS FOR CHRONIC, NON-COMMUNICABLE DISEASE AND DISORDERS ACROSS THE LIFESPAN: FOGARTY INTERNATIONAL RESEARCH TRAINING AWARD (D71)**

NIH: Fogarty International Center

### **Description:**

Participating components of the National Institutes of Health invite applications for their planning grants for chronic, non-communicable disease and disorders across the lifespan: Fogarty international research training planning award. Applicants should propose a plan to develop the components necessary for the D43 application, which supports research training to strengthen the capacity of institutions in low- and middle-income countries to conduct non-communicable disease research. Applications may be submitted by non-US institutions, based in low- and middle-income countries. The principal investigator for each project must also be the PI of at least one relevant active research award with at least 18 months remaining. Only one application for a planning grant may be submitted by an institution in a fiscal year under this call. The expected amount for individual awards will be up to \$27,000 per year for up to two years. Eligible costs include travel, salary, consultative fees and administrative costs. PAR-10-277.

**Closing date: 17 Dec 12 (Forecast)**

**Deadline information: !! Call has not yet been announced by sponsor but this is the approximate deadline we expect. Letters of intent due 17 March; full applications due 17 April 2013.**

**Posted date: 09 Sep 10**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$56,000**

**Award amount min: -**

**Award budget total: -**

### **Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-10-277.html>

### **Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-10-277>

### **Eligibility profile**

-----  
Nationality of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

### **Disciplines**

-----  
International Education & Training, Vocational & Technical Education, Disease Model, Training & Development, Research & Development (R&D), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Education (RAE Unit 68), Chronic Diseases

### **Contact Details**

-----  
Tel: +301 435 0714

Email: [GrantsInfo@nih.gov](mailto:GrantsInfo@nih.gov)



# **A** DVANCING EXCEPTIONAL RESEARCH ON HIV/AIDS (R01) NIH: National Institute on Drug Abuse

## **Description:**

The National Institute on Drug Abuse invites applications for its advancing exceptional research on HIV/Aids programme. This R01 funding opportunity announcement will support highly innovative R01 applications on HIV/Aids and drug abuse. The focus is on innovative research projects that have the potential to open new areas of HIV/Aids research or lead to new avenues for prevention and treatment of HIV/Aids among drug abusers. Applications are required to have a detailed research plan and preliminary data. This call is not limited to any one area of research. This FOA will complement the NIH avant-garde programme.

This FOA is open to both individual researchers and research teams. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. RFA-DA-13-008

**Closing date: 17 Dec 12**

**Deadline information: Letters of intent due by 17 November; full applications by 5pm local time, 17 December 2012.**

**Posted date: 15 Jun 12**

**Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc, Innovation grants**

**Award amount max: -**

**Award amount min: -**

**Award budget total: \$1,500,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-13-008.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-DA-13-008>

## **Eligibility profile**

-----  
Nationality of applicant institution: Any

## **Disciplines**

-----  
Drug & Substance Abuse, Transmission of HIV/AIDS, AIDS Counselling, AIDS, HIV Infection, Intervention, Agents for (Health & Safety & Medical), Intervention, Types of (Health & Safety & Medical), Disease Prevention, Preventive Medicine, Treatment, Medical, Pathogenesis, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, HIV Tests

## **Contact Details**

-----  
NIDA  
NIH  
6001 Executive Boulevard  
Room 5274, MSC 9581  
Bethesda, MD 20892  
Tel: +1 301 443 1470  
Fax: +1 301 594 5610  
Email: [jnormand@nida.nih.gov](mailto:jnormand@nida.nih.gov)



---

## **N**EW PROJECTS FOR EPI4K GENETICS AND GENOMICS OF HUMAN EPILEPSIES CENTRE WITHOUT WALLS (U01) *NIH: National Institute of Neurological Disorders and Stroke*

### **Description:**

The National Institute of Neurological Disorders and Stroke invites applications for its new projects for Epi4K genetics and genomics of human epilepsies centre without walls (U01) grants. The purpose of this U01 funding opportunity announcement is to encourage applications from investigators who wish to collaborate with the Epi4K genetics and genomics of human epilepsies centre without walls. Investigators with existing DNA samples from well characterised cohorts of epilepsy patients should propose next generation sequencing and analysis studies to identify novel sequence and copy number variants. The proposed studies must be within the scope of the CWOW programme and must use the extant infrastructure and resources of the Epi4K CWOW.

NINDS intends to fund between one and five awards, corresponding to a total of US\$1 million direct costs for fiscal year 2013. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is three years.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. RFA-NS-13-005.

**Closing date: 18 Dec 12**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 16 Jul 12**

**Award type:** Directed grants to institutions, research groups etc, Directed grants for individual investigators, Research centres

**Award amount max:** -

**Award amount min:** -

**Award budget total:** -

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-13-005.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-NS-13-005>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Population Genetics, Epilepsy, Neurological Disorders, Intervention, Types of (Health & Safety & Medical), Mapping, Genetic, Nucleic Acid Sequencing, DNA Mapping, DNA Sequencing, Genetics, Molecular Genetics, Drug-Receptor Interaction, Clinical Laboratory Sciences (RAE Unit 1), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Neuropsychology, Prescription Medicine/Drugs, Genetic Diseases, Movement Disorders

### **Contact Details**

-----  
NINDS

6001 Executive Boulevard, Room 2143

Rockville, MD 20852

Tel: +1 301 496 5745

Email: [katrina.gwinn@nih.gov](mailto:katrina.gwinn@nih.gov)



## CUTTING-EDGE BASIC RESEARCH AWARDS (R21)

NIH: National Institute on Drug Abuse

### Description:

The National Institute on Drug Abuse invites applications for its cutting-edge basic research awards (R21). These R21 grants support highly innovative or conceptually creative research that advances understanding of drug abuse and addiction and how to prevent and treat them. This scheme is specifically designed to support research that is high risk and potentially high impact and that is underrepresented or not included in NIDA's current portfolio. The proposed research should:

- test a highly novel and significant hypothesis for which there is significantly scant precedent or preliminary data and which, if confirmed, would have a substantial impact on current thinking;
- develop or adapt innovative techniques or methods for addiction research or have promising future applicability for drug abuse research.

This funding opportunity will use the R21 award mechanism. Budgets are limited to US\$125,000 per year in direct costs over a two-year project period. Domestic and foreign for-profit and nonprofit organizations and public or private institutions may apply. PAR-12-086 (replaces PAR-09-222)

**Closing date: 20 Dec 12**

**Deadline information: Applications are due 5pm local time of applicant organization on deadline date.**

**Deadlines on: 20 August 2012, 20 December 2012, 20 August 2013, 20 December 2013, 20 August 2014, 19 December 2014.**

**Posted date: 30 Jan 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$250,000**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-086.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-086>

### Eligibility profile

Nationality of applicant institution: Any

### Disciplines

Addictions, Drug & Substance Abuse, Psychology, Neurophysiology, Pharmacology, Neuropharmacology, Neuroscience, Community-based Clinical Subjects (RAE Unit 2), Physiology (RAE Unit 7), Pharmacology (RAE Unit 8), Psychology (RAE Unit 13), Biological Sciences (RAE Unit 14), Neurobiology, Community-based Clinical Subjects, Physiology

### Contact Details

Division of Basic Neuroscience and Behavioral Research

NIDA

6001 Executive Boulevard, Room 4282, MSC 9555

Bethesda, MD 20892-9555

Tel: +1 301 435 1315

Fax: +1 301 594 6043

Email: [svolman@mail.nih.gov](mailto:svolman@mail.nih.gov)